Methods for prevention and treatment of inflammation using anti-chemokine antibodies

Abstract

It is possible to inhibit inflammatory processes by administration of antibodies to chemokines. Identification of chemokines which are over-produced makes it possible to block specific chemokine activity using antibodies to the over-expressed chemokines.

1 - 15 . (canceled) 
     
     
         16 . A method of treating a mammal with inflammatory disease, comprising:
 a) exposing a tissue sample from said mammal to an antibody which binds specifically to CCL25, or an antibody which binds specifically to CXCL13, or both antibodies;   b) determining a level of expression of CCL25, or CXCL13 or both based on binding of said antibody to said tissue sample; and   c) if over-expression of CCL25 or CXCL13 or both are detected in said tissue sample of said mammal, administering to said mammal an effective amount of an antibody which binds specifically to CCL25, or an antibody which binds specifically to CXCL13, or both antibodies for the treatment of said inflammatory disease.   
     
     
         17 . The method of  claim 16 , wherein said mammal is a human or humanized antibody. 
     
     
         18 . The method of  claim 16 , wherein in step c, said antibody or antibodies are humanized antibodies. 
     
     
         19 . The method of  claim 16 , wherein in step c, said antibody or antibodies are chimeric antibodies. 
     
     
         20 . The method of  claim 16 , wherein in step c, said antibody or antibodies are administered directly into an inflamed tissue. 
     
     
         21 . The method of  claim 16 , wherein in step c, said antibody or antibodies are administered parenterally. 
     
     
         22 . The method of  claim 16 , wherein in step c, said antibody or antibodies are administered systemically. 
     
     
         22 . The method of  claim 16 , wherein in step c, said antibody or antibodies are administered in a liquid carrier. 
     
     
         23 . The method of  claim 16 , wherein in step c, said antibody or antibodies are administered on a solid support. 
     
     
         24 . The method of  claim 16 , wherein said inflammatory disease is selected from the group consisting of anaphylaxis, septic shock, arthritis, asthma, allergies, atherosclerosis, bronchitis, chronic pulmonary obstructive disease, delayed type hypersensitivity, dermatitis, diabetes, graft rejection, Grave's disease, Hashimoto's thyroiditis, inflammatory bowel diseases, interstitial cystitis, multiple sclerosis, myasthemia gravis, pneumonitis, psoriasis, nephritis, rhinitis, spondyloarthropathies, scheroderma, systemic lupus erythematosus, and throiditis. 
     
     
         25 . A method of treating a mammal with inflammatory disease, comprising:
 a) determining the level of CCL25 or CXCL13 or both in a tissue sample in said mammal using PCR; and   b) if over-expression of CCL25 or CXCL13 or both is detected in said tissue sample of said mammal, administering to said mammal an effective amount of an antibody which binds specifically to CCL25, an antibody which binds specifically to CXCL13, or both antibodies for the treatment of said inflammatory disease.   
     
     
         26 . The method of  claim 25 , wherein said antibody or antibodies are administered directly into an inflamed tissue. 
     
     
         27 . The method of  claim 25 , wherein said antibody or antibodies are administered systemically. 
     
     
         28 . The method of  claim 25 , wherein in step c, said antibody or antibodies are administered parenterally. 
     
     
         29 . The method of  claim 25 , wherein said antibody or antibodies are administered on a solid support. 
     
     
         30 . The method of  claim 25 , wherein said antibody or antibodies are human or humanized antibodies. 
     
     
         31 . The method of  claim 25 , wherein in step c, said antibody or antibodies are chimeric antibodies. 
     
     
         32 . The method of  claim 25 , wherein said inflammatory disease is selected from the group consisting of anaphylaxis, septic shock, arthritis, asthma, allergies, atherosclerosis, bronchitis, chronic pulmonary obstructive disease, delayed type hypersensitivity, dermatitis, diabetes, graft rejection, Grave's disease, Hashimoto's thyroiditis, inflammatory bowel diseases, interstitial cystitis, multiple sclerosis, myasthemia gravis, pneumonitis, psoriasis, nephritis, rhinitis, spondyloarthropathies, scheroderma, systemic lupus erythematosus, and throiditis.